

# Alba Ariela Brandes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3594538/publications.pdf>

Version: 2024-02-01

263  
papers

47,520  
citations

14124

69  
h-index

2018

212  
g-index

276  
all docs

276  
docs citations

276  
times ranked

35221  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	0.6	150
2	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. <i>Immunotherapy</i> , 2022, 14, 169-172.	1.0	5
3	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. <i>Cancers</i> , 2022, 14, 333.	1.7	6
4	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. <i>Acta Neuropathologica Communications</i> , 2022, 10, 1.	2.4	28
5	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. <i>Frontiers in Oncology</i> , 2022, 12, 852950.	1.3	9
6	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. <i>Neuro-Oncology Practice</i> , 2022, 9, 310-316.	1.0	7
7	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
8	Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. <i>Neuro-Oncology</i> , 2022, 24, 2159-2169.	0.6	7
9	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2545.	0.8	23
10	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , 2021, 11, 342.	1.3	15
11	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , 2021, 145, 171-178.	1.3	7
12	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	1.0	9
13	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. <i>Tumori</i> , 2021, , 030089162110172.	0.6	1
14	IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. <i>Pathology Research and Practice</i> , 2021, 221, 153445.	1.0	6
15	The clinical and prognostic role of ALK in glioblastoma. <i>Pathology Research and Practice</i> , 2021, 221, 153447.	1.0	5
16	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 457-473.	1.6	19
17	Molecular alterations in pancreatic tumors. <i>World Journal of Gastroenterology</i> , 2021, 27, 2710-2726.	1.4	16
18	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , 2021, 26, 865-878.	1.9	39

#	ARTICLE	IF	CITATIONS
19	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , 2021, 10, CNS72.	1.2	54
20	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Tj ETQq0 0 0 rgBT /Overlock 10 <i>Oncology, The</i> , 2021, 22, 813-823.	5.1	132
21	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	1.7	16
22	Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward. <i>Immunotherapy</i> , 2021, 13, 879-883.	1.0	16
23	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021, 41, 757-773.	1.1	1
24	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04604.	0.2	4
25	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	2
26	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1265-1272.	1.1	4
27	Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1185-1194.	1.2	7
28	Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients. <i>Neurosurgery</i> , 2021, 89, 1042-1051.	0.6	2
29	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2021, 3, e784-e794.	5.9	52
30	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. <i>Diagnostics</i> , 2021, 11, 1852.	1.3	11
31	Burnout in medical oncology during the COVID-19 pandemic. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 351-353.	1.1	3
32	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1333-1353.	1.1	9
33	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , 2020, 7, 668-675.	1.0	5
34	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020, 9, 8373-8385.	1.3	19
35	Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. <i>Immunotherapy</i> , 2020, 12, 1111-1114.	1.0	17
36	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. <i>European Journal of Cancer</i> , 2020, 137, 10-17.	1.3	25

#	ARTICLE	IF	CITATIONS
37	Glioneuronal tumors: clinicopathological findings and treatment options. <i>Future Neurology</i> , 2020, 15, .	0.9	7
38	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020, 10, 996.	1.3	14
39	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 785-795.	1.1	23
40	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	3.4	805
41	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , The, 2020, 21, e317-e329.	5.1	69
42	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. <i>Diagnostics</i> , 2020, 10, 265.	1.3	6
43	How to face cancer treatment in the COVID-19 era. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 429-432.	1.1	5
44	Predictive markers of immune response in glioblastoma: hopes and facts. <i>Future Oncology</i> , 2020, 16, 1053-1063.	1.1	13
45	Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2020, 149, 65-71.	1.4	14
46	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020, 16, 1433-1439.	1.1	14
47	Immunotherapy in elderly patients: should we stay or should we go?. <i>Future Oncology</i> , 2020, 16, 973-974.	1.1	3
48	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa147.	0.4	1
49	Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?. <i>Child's Nervous System</i> , 2019, 35, 2279-2287.	0.6	3
50	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019, 21, 1447-1457.	0.6	35
51	Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. <i>Future Oncology</i> , 2019, 15, 2595-2601.	1.1	5
52	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 116, 190-198.	1.3	22
53	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019, 92, e2754-e2763.	1.5	9
54	Postsurgical Approaches in Lowâ€Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. <i>Oncologist</i> , 2019, 24, 664-670.	1.9	3

#	ARTICLE	IF	CITATIONS
55	EANOâ€“EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology, The</i> , 2019, 20, e715-e728.	5.1	56
56	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019, 20, 110-119.	5.1	238
57	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528.	1.9	47
58	Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. <i>Journal of Neuro-Oncology</i> , 2018, 139, 383-388.	1.4	12
59	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. <i>World Neurosurgery</i> , 2018, 112, e342-e347.	0.7	36
60	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615.	3.9	76
61	The burden of oncology promises not kept in glioblastoma. <i>Future Neurology</i> , 2018, 13, 1-4.	0.9	3
62	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	0.6	74
63	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , 2018, 14, 1559-1567.	1.1	17
64	The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. <i>Oncology and Therapy</i> , 2018, 6, 105-108.	1.0	10
65	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. <i>Future Oncology</i> , 2018, 14, 1063-1069.	1.1	11
66	Role of <i>MGMT</i> Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. <i>Oncologist</i> , 2017, 22, 432-437.	1.9	61
67	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	0.6	137
68	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1542-1552.	0.6	130
69	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 376, 1027-1037.	13.9	810
70	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O <sup>6</sup> -Methylguanineâ€“DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351.	0.8	110
71	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1373-1385.	5.1	776
72	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. <i>Journal of Neuro-Oncology</i> , 2017, 135, 245-254.	1.4	17

#	ARTICLE	IF	CITATIONS
73	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017, 390, 1645-1653.	6.3	307
74	Immunotherapy in head and neck cancer: evidence and perspectives. <i>Immunotherapy</i> , 2017, 9, 1351-1358.	1.0	16
75	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963.	13.9	670
76	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , 2017, 31, 675-684.	2.7	24
77	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	1.8	32
78	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017, 8, 55575-55581.	0.8	10
79	ACTR-01. THE ROLE OF CLINICAL CHARACTERISTICS IN LOW GRADE GLIOMAS PATIENTS IN THE ERA OF MOLECULAR BIOMARKERS: A STUDY FROM GRUPPO ITALIANO COOPERATIVO DI NEURO-ONCOLOGIA (GICNO). <i>Neuro-Oncology</i> , 2016, 18, vi1-vi1.	0.6	0
80	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1304-1312.	0.6	71
81	Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806.	3.2	105
82	Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology, The</i> , 2016, 17, 1533-1542.	5.1	97
83	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology, The</i> , 2016, 17, 1521-1532.	5.1	396
84	Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. <i>Current Treatment Options in Oncology</i> , 2016, 17, 49.	1.3	48
85	The role of gender in glioblastoma: does it matter?. <i>Future Neurology</i> , 2016, 11, 197-199.	0.9	1
86	Nitrosoureas in the Management of Malignant Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 13.	2.0	43
87	Patient outcomes following second surgery for recurrent glioblastoma. <i>Future Oncology</i> , 2016, 12, 1039-1044.	1.1	25
88	Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. <i>Journal of Neuro-Oncology</i> , 2016, 128, 157-162.	1.4	23
89	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1146-1156.	0.6	197
90	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 115-120.	1.1	31

#	ARTICLE	IF	CITATIONS
91	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2001-2001.	0.8	46
92	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2019-2019.	0.8	14
93	Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.. Journal of Clinical Oncology, 2016, 34, 2020-2020.	0.8	14
94	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG) Tj ETQ q08 0 rgBT4/Overlock	0.8	0
95	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	0.8	8
96	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG) Tj ETQ q08 0 rgBT4/Overlock	0.8	0
97	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	0.8	20
98	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. Oncotarget, 2016, 7, 55169-55180.	0.8	45
99	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget, 2016, 7, 33210-33219.	0.8	128
100	The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study.. Journal of Clinical Oncology, 2016, 34, 2032-2032.	0.8	0
101	New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Critical Reviews in Oncology/Hematology, 2015, 94, 348-359.	2.0	43
102	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. Oncologist, 2015, 20, 166-175.	1.9	66
103	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2015, 16, 561-568.	5.1	141
104	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	5.1	582
105	The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials. CNS Oncology, 2015, 4, 117-119.	1.2	5
106	Bevacizumab in recurrent glioblastoma: open issues. Future Oncology, 2015, 11, 2655-2665.	1.1	9
107	Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. Journal of Clinical Pathology, 2015, 68, 859-869.	1.0	16
108	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. Journal of Thoracic Oncology, 2015, 10, 1437-1443.	0.5	163

#	ARTICLE	IF	CITATIONS
109	Post progression survival in glioblastoma: where are we?. Journal of Neuro-Oncology, 2015, 121, 399-404.	1.4	10
110	Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.. Journal of Clinical Oncology, 2015, 33, 2006-2006.	0.8	7
111	A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2014-2014.	0.8	5
112	Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. Journal of Clinical Oncology, 2015, 33, 2015-2015.	0.8	25
113	Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREC (ML25739) phase II study.. Journal of Clinical Oncology, 2015, 33, 2047-2047.	0.8	1
114	Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients.. Journal of Clinical Oncology, 2015, 33, 8079-8079.	0.8	0
115	The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Research, 2015, 35, 1743-8.	0.5	42
116	Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment. PLoS ONE, 2014, 9, e103883.	1.1	135
117	Shedding Light on Adult Medulloblastoma: Current Management and Opportunities for Advances. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e82-e87.	1.8	14
118	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. Future Oncology, 2014, 10, 1137-1145.	1.1	16
119	The role of systemic and targeted therapies in brain metastases. Expert Review of Anticancer Therapy, 2014, 14, 93-103.	1.1	6
120	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. Neuro-Oncology Practice, 2014, 1, 166-171.	1.0	23
121	Resistance to antiangiogenic therapies. Future Oncology, 2014, 10, 1417-1425.	1.1	10
122	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients. Journal of Thoracic Oncology, 2014, 9, 733-737.	0.5	28
123	Bevacizumab plus Radiotherapyâ€“Temozolomide for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 709-722.	13.9	2,078
124	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108.	5.1	800
125	The metastatic process: a kaleidoscope of concepts. Future Oncology, 2014, 10, 697-698.	1.1	2
126	NI-26 * COMPARATIVE ANALYSIS OF THE RANO AND MACDONAD'S CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.. Neuro-Oncology, 2014, 16, v143-v144.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Optimal management of elderly patients with glioblastoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 350-357.	3.4	131
128	Second surgery for recurrent glioblastoma: advantages and pitfalls. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 583-587.	1.1	29
129	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. <i>Future Oncology</i> , 2013, 9, 1653-1664.	1.1	10
130	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 344-350.	0.8	1,003
131	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. <i>European Journal of Cancer</i> , 2013, 49, 3477-3485.	1.3	51
132	Metastatic process: the seed and the soil from bench to bedside. <i>Future Oncology</i> , 2013, 9, 1597-1598.	1.1	0
133	Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2005-2005.	0.8	26
134	Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 50	0.8	0
135	Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF- $\beta$ ) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2061-2061.	0.8	9
136	Final results from a large prospective Italian population study on glioblastoma and correlations with MGMT status: The Project of Emilia-Romagna Region in Neuro-oncology (PERNO).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2048-2048.	0.8	0
137	A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology;) Tj ETQq1 1 0.784314 rgBT /Overlook methylation status in the elderly population.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2021-2021.	0.8	0
138	Brain metastases from non-small-cell lung cancer: is there room for improvement?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 421-423.	1.1	7
139	Treatment decisions in elderly patients with glioblastoma. <i>Nature Reviews Neurology</i> , 2012, 8, 664-665.	4.9	9
140	Cytologically confirmed splenic metastases in breast cancer. <i>Future Oncology</i> , 2012, 8, 1495-1500.	1.1	3
141	CNS Oncology: reflecting a rapidly changing landscape. <i>CNS Oncology</i> , 2012, 1, 1-2.	1.2	0
142	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 1503-1510.	0.6	58
143	Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. <i>European Journal of Cancer</i> , 2012, 48, 896-903.	1.3	20
144	Epidemiology of glial and non-glial brain tumours in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1532-1542.	1.3	248

#	ARTICLE	IF	CITATIONS
145	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. <i>European Journal of Cancer</i> , 2012, 48, 1176-1184.	1.3	161
146	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 20-26.	2.2	0
147	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1429-1435.	1.1	35
148	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , 2012, 60, 885-894.	1.6	44
149	Anaplastic gliomas at first recurrence: Outcome analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2061-2061.	0.8	2
150	Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7550-7550.	0.8	3
151	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061,) Tj ETQq1ol8.784374 rgBT		
152	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2-2.	0.8	19
153	Natural history of glioblastoma in the modern era: Longitudinal results from a large prospective Italian register.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2057-2057.	0.8	0
154	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2-2.	0.8	6
155	Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. <i>Oncology</i> , 2012, 26, 1083-91.	0.4	4
156	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1713-1717.	1.1	3
157	Medulloblastomas in adults. <i>Current Opinion in Neurology</i> , 2011, 24, 626-632.	1.8	16
158	Primary Brain Tumors in the Elderly Population. <i>Current Treatment Options in Neurology</i> , 2011, 13, 427-435.	0.7	8
159	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	0.8	182
160	Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 657-660.	1.1	8
161	Advances in malignant glioma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 739-753.	2.5	16
162	New Agents and New End Points for Recurrent Gliomas. <i>Journal of Clinical Oncology</i> , 2011, 29, e245-e246.	0.8	6

#	ARTICLE	IF	CITATIONS
163	Medulloblastomas. , 2011, , 415-433.		0
164	Gangliogliomas: recent advances in classification and treatment. Future Neurology, 2010, 5, 557-568.	0.9	2
165	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nature Reviews Neurology, 2010, 6, 39-51.	4.9	644
166	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. BMC Cancer, 2010, 10, 48.	1.1	33
167	O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-Oncology, 2010, 12, 283-288.	0.6	110
168	Genetic variation in pediatric and adult brain tumors. Nature Reviews Neurology, 2010, 6, 653-654.	4.9	5
169	Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies. Oncologist, 2010, 15, 683-694.	1.9	43
170	EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. European Journal of Cancer, 2010, 46, 348-354.	1.3	71
171	<i>IDH1</i> and <i>IDH2</i> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 2010, 16, 1597-1604.	3.2	364
172	Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert Review of Anticancer Therapy, 2010, 10, 179-184.	1.1	12
173	<i>MGMT</i> Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2009, 27, 5881-5886.	0.8	232
174	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology, 2009, 11, 737-746.	0.6	71
175	Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Review of Anticancer Therapy, 2009, 9, 613-619.	1.1	33
176	Bevacizumab in brain tumors: ready for primetime?. Future Oncology, 2009, 5, 1183-1184.	1.1	5
177	Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034. Journal of Clinical Oncology, 2009, 27, 1268-1274.	0.8	503
178	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma. Cancer, 2009, 115, 3512-3518.	2.0	207
179	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology, 2009, 64, 769-75.	1.1	89
180	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Critical Reviews in Oncology/Hematology, 2009, 71, 165-179.	2.0	56

#	ARTICLE	IF	CITATIONS
181	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. <i>Lung Cancer</i> , 2009, 64, 199-206.	0.9	20
182	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology</i> , The, 2009, 10, 459-466.	5.1	6,451
183	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet</i> , The, 2009, 374, 1512-1520.	6.3	588
184	Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With <i>MGMT</i> Promoter Methylation Status. <i>Journal of Clinical Oncology</i> , 2009, 27, 1275-1279.	0.8	311
185	Treatment of recurrent high-grade gliomas. <i>Current Opinion in Neurology</i> , 2009, 22, 657-664.	1.8	30
186	Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapeutic agents changed the clinical outcome?. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 212-221.	2.0	33
187	Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 89, 179-185.	1.4	79
188	Glioblastoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 139-152.	2.0	156
189	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <i>Lancet Oncology</i> , The, 2008, 9, 29-38.	5.1	487
190	Adjuvant temozolomide: how long and how much?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 663-665.	1.1	2
191	Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments. <i>Clinical Cancer Research</i> , 2008, 14, 957-960.	3.2	125
192	Association between response to primary treatments and <i>MGMT</i> status in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1781-1786.	1.1	7
193	Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4659-4665.	0.8	194
194	<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 2192-2197.	0.8	760
195	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. <i>Neuro-Oncology</i> , 2008, 10, 361-367.	0.6	233
196	Trastuzumab in CNS progressive metastatic breast cancer. <i>Future Oncology</i> , 2007, 3, 367-369.	1.1	1
197	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>British Journal of Cancer</i> , 2007, 96, 1047-1051.	2.9	179
198	Challenges and progress in the treatment of adult medulloblastomas. <i>Future Oncology</i> , 2007, 3, 115-117.	1.1	0

#	ARTICLE	IF	CITATIONS
199	Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 5723-5730.	0.8	100
200	Prognostic Value of Health-Related Quality-of-Life Data in Predicting Survival in Patients With Anaplastic Oligodendrogliomas, From a Phase III EORTC Brain Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 5731-5737.	0.8	63
201	Adjuvant therapy in glioblastomas: false steps and real advances. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 607-608.	1.1	1
202	Long-term results of a prospective study on the treatment of medulloblastoma in adults. <i>Cancer</i> , 2007, 110, 2035-2041.	2.0	126
203	Prognostic factors for anaplastic astrocytomas. <i>Journal of Neuro-Oncology</i> , 2007, 81, 295-303.	1.4	33
204	New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1129-1131.	1.1	2
205	Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 2715-2722.	0.8	690
206	Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. <i>Cancer Treatment Reviews</i> , 2006, 32, 9-27.	3.4	59
207	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. <i>European Journal of Cancer</i> , 2006, 42, 2499-2503.	1.3	111
208	Raltitrexed+erlotinib salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. <i>British Journal of Cancer</i> , 2006, 94, 785-791.	2.9	73
209	The development of platinum compounds and their possible combination. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 59-75.	2.0	94
210	Glioblastoma in the elderly: Current and future trends. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 256-266.	2.0	38
211	Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 2563-2569.	0.8	447
212	Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 4746-4753.	0.8	171
213	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. <i>Neuro-Oncology</i> , 2006, 8, 253-260.	0.6	67
214	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). <i>British Journal of Cancer</i> , 2006, 95, 1155-1160.	2.9	221
215	A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Cancer</i> , 2005, 104, 143-148.	2.0	75
216	Novel therapeutics in adult malignant brain gliomas. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 643-658.	1.9	4

#	ARTICLE	IF	CITATIONS
217	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996.	13.9	17,395
218	Adjuvant chemotherapy in the treatment of high grade gliomas. <i>Cancer Treatment Reviews</i> , 2005, 31, 79-89.	3.4	61
219	Adding temozolomide to radiotherapy prolongs survival in people with glioblastoma. <i>Cancer Treatment Reviews</i> , 2005, 31, 577-581.	3.4	1
220	Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Journal of Clinical Oncology</i> , 2004, 22, 4779-4786.	0.8	113
221	First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Journal of Clinical Oncology</i> , 2004, 22, 1598-1604.	0.8	97
222	Treatment of brain metastases in uncommon tumors. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 783-793.	1.1	13
223	Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. <i>British Journal of Cancer</i> , 2004, 90, 353-358.	2.9	130
224	Review of the prognostic factors in medulloblastoma of children and adults. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 121-128.	2.0	51
225	The pathogenesis and treatment of brain metastases: a comprehensive review. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 199-215.	2.0	130
226	A multicenter study of the prognosis and treatment of adult brain ependymal tumors. <i>Cancer</i> , 2004, 100, 1221-1229.	2.0	105
227	Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. <i>Cancer</i> , 2004, 101, 2079-2085.	2.0	37
228	Chemotherapy in brain metastases of lung and breast cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 101-110.	0.2	0
229	Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. <i>Anticancer Research</i> , 2004, 24, 3221-4.	0.5	33
230	Introduction: future trends in the treatment of brain tumors. <i>Seminars in Oncology</i> , 2003, 30, 1-3.	0.8	1
231	The treatment of elderly patients with high-grade gliomas. <i>Seminars in Oncology</i> , 2003, 30, 58-62.	0.8	37
232	State-of-the-art treatment of high-grade brain tumors. <i>Seminars in Oncology</i> , 2003, 30, 4-9.	0.8	94
233	A prospective study on glioblastoma in the elderly. <i>Cancer</i> , 2003, 97, 657-662.	2.0	169
234	The treatment of adults with medulloblastoma: a prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 755-761.	0.4	82

#	ARTICLE	IF	CITATIONS
235	Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. <i>Journal of Clinical Oncology</i> , 2003, 21, 2525-2528.	0.8	288
236	Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 167-178.	1.1	3
237	Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 615-620.	1.1	11
238	Current management and prognostic factors for adult ependymoma. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 537-545.	1.1	21
239	Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study. <i>Oncology</i> , 2002, 63, 38-41.	0.9	55
240	Non-cytotoxic therapies for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2002, 58, 57-69.	1.4	21
241	Temozolomide in glioblastoma multiforme of the elderly. <i>Tumori</i> , 2002, 88, S69-70.	0.6	0
242	High-Dose Chemotherapy with Bone Marrow Rescue for High-Grade Gliomas in Adults. <i>Cancer Investigation</i> , 2001, 19, 41-48.	0.6	20
243	Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. <i>Annals of Oncology</i> , 2001, 12, 255-258.	0.6	77
244	Accuracy of technetium-99m sestamibi scintimammography and X-ray mammography in premenopausal women with suspected breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1776-1780.	3.3	16
245	Fine-needle aspiration cytology of adrenal masses in noncancer patients. <i>Cancer</i> , 2001, 93, 323-329.	2.0	78
246	Changing boundaries in the treatment of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 357-370.	1.1	9
247	Temozolomide in Patients with High Grade Gliomas. <i>Oncology</i> , 2000, 59, 181-186.	0.9	26
248	Chemotherapy in patients with recurrent and progressive central neurocytoma. , 2000, 88, 169-174.		104
249	Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management. <i>Journal of Neuro-Oncology</i> , 2000, 47, 85-92.	1.4	14
250	The treatment of cranial germ cell tumours. <i>Cancer Treatment Reviews</i> , 2000, 26, 233-242.	3.4	67
251	Procarbazine and High-Dose Tamoxifen as a Second-Line Regimen in Recurrent High-Grade Gliomas: A Phase II Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 645-645.	0.8	82
252	Medulloblastoma in adults: clinical characteristics and treatment. <i>Cancer Treatment Reviews</i> , 1999, 25, 3-12.	3.4	54

#	ARTICLE	IF	CITATIONS
253	Reoperation in Recurrent High-Grade Gliomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 387-390.	0.6	21
254	Unusual nasal and orbital involvement of glioblastoma multiforme: a case report and review of the literature. Journal of Neuro-Oncology, 1998, 36, 179-183.	1.4	7
255	Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme. , 1998, 82, 355-361.		44
256	Treatment of High-Grade Gliomas in the Elderly. Oncology, 1998, 55, 1-6.	0.9	27
257	Phase II Trial with BCNU plus $\hat{I}\pm$ -Interferon in Patients with Recurrent High-Grade Gliomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 364-367.	0.6	37
258	Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. Journal of Neuro-Oncology, 1996, 30, 247-55.	1.4	21
259	The Role of Chemotherapy in Recurrent Malignant Gliomas: An Overview. Cancer Investigation, 1996, 14, 551-559.	0.6	62
260	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer, 1990, 65, 2631-2634.	2.0	27
261	Cisplatin plus Vindesine versus Cisplatin plus VP16 versus Doxorubicin plus Cytosin in Non-Small-Cell Carcinoma of the Lung. A Randomized Study. Tumori, 1986, 72, 417-425.	0.6	11
262	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. Immunotherapy, 0, , .	1.0	3
263	Tumor-Associated Microenvironment of Adult Gliomas: A Review. Frontiers in Oncology, 0, 12, .	1.3	7